difference of semaglutide and tirzepatide Comparative safety side effects and tirzepatide: Implications for clinical decision-making in obesity management Semaglutide vs Tirzepatide Compound: Key

For more information, visit klowenbraces.com

Appropriate vaccinations and bone health monitoring are also important aspects of comprehensive care

25 mg/day oral Tirzepatide 15 mg/week Retatrutide 12 mg/week Liraglutide 3.0 mg/day Factor Peak trial weight loss Semaglutide -14.9% at 68 wks (STEP 1) Tirzepatide -22.5% at 72 wks (SURMOUNT-1) Retatrutide -28.7% at 68 wks (TRIUMPH-4) Liraglutide -8% at 56 wks (SCALE) Factor FDA status (June 2026) Semaglutide Approved (T2D, obesity, CVD, MASH, CKD, oral) Tirzepatide Approved (T2D, obesity) Retatrutide Investigational - Phase 3 Liraglutide Approved (Saxenda obesity, Victoza T2D) Factor CV outcomes data Semaglutide Yes - SELECT (20% MACE drop) Tirzepatide SURPASS-CVOT ongoing Retatrutide TRIUMPH-3 ongoing Liraglutide Yes - LEADER (13% MACE drop) These compounds are not interchangeable

Use your dedicated support team to ask questions as soon as they arise

It is supplied as a sterile, lyophilised peptide for in vitro laboratory research only and is not intended for human use